Abstract:
Pulmonary inflammatory responses lie under circadian control; however the importance of circadian mechanisms in fibrosis is not understood. Here, we identify a striking change to these mechanisms resulting in a gain of amplitude and lack of synchrony within pulmonary fibrotic tissue. These changes result from an infiltration of mesenchymal cells, an important cell type in the pathogenesis of pulmonary fibrosis. Mutation of the core clock protein REVERBα in these cells exacerbated the development of bleomycin-induced fibrosis, whereas mutation of REVERBα in club or myeloid cells had no effect on the bleomycin phenotype. Knockdown of REVERBα revealed regulation of the poorly described transcription factor TBPL1. Both
REVERBα and TBPL1 altered integrinβ1 focal adhesion formation, resulting in increased myofibroblast activation. The translational importance of our findings was established through analysis of two human cohorts. In the UK Biobank circadian strain markers (sleep length, chronotype and shift work) are associated with pulmonary fibrosis making them novel risk factors. In a separate cohort REVERBα expression was increased in human idiopathic pulmonary fibrosis (IPF) lung tissue.
Pharmacological targeting of REVERBα inhibited myofibroblast activation in IPF fibroblasts and collagen secretion in organotypic cultures from IPF patients, suggesting targeting REVERBα could be a viable therapeutic approach.
Significance: The circadian clock plays an essential role in energy metabolism, and inflammation. In contrast the importance of the clock in the pathogenesis of fibrosis remains poorly explored. This study describes a striking alteration in circadian biology during pulmonary fibrosis where the relatively arrhythmic alveolar structures gain circadian but desynchronous rhythmicity due to infiltration by fibroblasts.
Disruption of the clock in these cells, which are not widely implicated in circadian pathophysiology, results in a pro-fibrotic phenotype. Translation of these findings in humans revealed previously unrecognised important circadian risk factors for pulmonary fibrosis (sleep length, chronotype and shift work). In addition, targeting REVERBα repressed collagen secretion from human fibrotic lung tissue making this protein a promising therapeutic target.
Introduction:
The lung is highly circadian, resulting in temporal gating of a number of inflammatory (1-3) and anti-oxidant responses (4) . Local timing is dominated by non-ciliated, bronchial epithelial cells (club cells) (2) and alveolar macrophages (3, 5) . In contrast, alveolar structures typically show only weak circadian oscillations (6) , with implications for the pathogenesis of diseases such as pulmonary fibrosis. Despite this, genetic disruption of the Clock gene (4), impairing circadian oscillations, exaggerates early mouse pulmonary responses to bleomycin challenge; a model of pulmonary fibrosis (7) .
Pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF), is frequently fatal with existing treatments slowing progression rather than curing the disease (8) . The causes and non-genetic risk factors for IPF are poorly understood, with several studies implicating age, sex, smoking and more recently air pollution (9) . IPF is characterized histologically by the development of fibroblastic foci in the lung parenchyma (10) . Cells in these foci are typically activated myofibroblasts (11) derived from multiple sources (12, 13) , including pulmonary fibroblasts and pericytes (11, 14) . Myofibroblasts secrete collagen resulting in abnormal lung function and are characterized by increased focal adhesion formation and acquisition of a contractile cytoskeleton with alpha smooth muscle actin (αSMA)-positive stress fibers (15) . In addition to fibroblasts, pulmonary fibrosis involves other cell types e.g. club cells (9) and macrophages (16) regulating the accumulation of fibroblasts and therefore the deposition of the extracellular matrix. As these cell types maintain autonomous circadian oscillations (2, 5) , examination of circadian factors and mechanisms in the pulmonary fibrotic response is warranted.
The circadian clock is an internal timing mechanism (17), allowing temporal segregation of both pathophysiological and physiological programs (18, 19) . At the cellular level the circadian clock consists of a transcription-translation feedback loop (20) , in which the positive elements CLOCK and BMAL1 drive expression of two negative feedback arms controlled by PERIOD/CRYPTOCHROME (PER/CRY) and the two paralogues REVERBα and REVERBβ. In turn these negative feedback arms repress BMAL1/CLOCK heterodimer transactivation function (PER/CRY), or BMAL1 expression (REVERBα/β). The resulting 24-hour oscillations in protein expression can be disrupted through environmental disruption (e.g. shift-work schedules), or genetic deletion of core clock components producing inflammatory and metabolic phenotypes (5, 21, 22) .
Here, we show that fibrotic mouse lungs exhibited amplified, but desynchronous circadian rhythms, with a dominant role for myofibroblasts. Disruption of the core clock protein REVERBα in fibroblastic cells resulted in exaggerated pulmonary fibrotic response to bleomycin in mice. In culture, REVERBα knockdown resulted in increased myofibroblast differentiation via the transcription factor TBPL1, through altering the formation of integrinβ1 focal adhesion expression. Furthermore exposure to circadian stresses such as late chronotype, shift work, and altered sleep duration are all associated with idiopathic pulmonary fibrosis and clock gene expression is altered in IPF versus normal human lung. Targeting of REVERBα by a synthetic ligand repressed myofibroblast differentiation and collagen secretion in cultured fibroblasts and lung slices obtained from patients with lung fibrosis.
Results:
Myofibroblasts drive high amplitude, but desynchronous circadian oscillations in fibrotic lung.
Precision cut lung slices from transgenic mPER2::LUC mice (2) were used to track circadian oscillations in real-time after bleomycin-induction of fibrosis ( Fig. 1A , S1A,B, Video S1). Fibrotic areas were identified by loss of lung architecture in the brightfield image, and confirmed with increased collagen deposition when the slices were fixed for histology ( Fig. S1A,B ). The amplitude of PER2 oscillations in the fibrotic areas was increased compared to non-fibrotic parenchyma lung ( Fig. 1A-B ,D). The fibrotic parenchyma also had greater phase desynchrony compared to regions in the non-fibrotic parenchyma (Fig. 1C ). One possible explanation for these changes is the cell density in the fibrotic parenchyma. To explore this precision cut lung sections (PCLS) were stained with Hoechst. There was a greater intensity of staining in fibrotic areas compared to non-fibrotic areas, but this did not correlate with bioluminescence ( Fig. S1C-E ). Another possible explanation is infiltration by a more rhythmic cell type, therefore we deleted the essential core clock component BMAL1 (23) in both fibroblasts and club cells to ablate cell-autonomous rhythms. BMAL1 deletion in club cells (CCSP-Bmal1), the main oscillatory cells in the lung (6), had no effect on the increased amplitude seen in fibrotic regions ( Fig. 1D ,G, S1G, Video S2).
In contrast, BMAL1 deletion in pericyte/fibroblast lineage (Pdgfrb-Bmal1 -/-) restored the amplitude of lung oscillations in fibrotic lung to levels measured in unaffected lung tissue ( Fig. 1E -G, S1F, Video S3).
To test if pro-fibrotic factors are capable of modifying circadian signals between cells, lung slices and fibroblasts were treated with TGFβ, and inflated to mimic changes in the cellular mechanoenvironment ( Fig. S2A ). TGFβ induced changes in circadian phase, with the magnitude of effect being dependent on concentration and phase ( Fig. S2B,C ). Lung inflation also increased the amplitude of the PER2::LUC oscillation ( Fig. S2D ).
REVERBα in fibroblasts suppresses the development of pulmonary fibrosis
REVERBα is an orphan nuclear receptor, and both an essential core clock factor, and major clock output pathway. Its function can be disrupted by deletion of its DNA binding domain, and small molecular ligands are available to modulate activity.
Therefore we deleted the REVERBα DNA binding domain ( Fig 
Knockdown of REVERBα in vitro enhances myofibroblast activation through the transcription factor TBPL1
Next, we set out to identify REVERBα gene targets using siRNA knockdown of REVERBα in both mouse and human lung fibroblast cell lines ( Fig. S4A ). REVERBα knockdown resulted in myofibroblast activation in lung fibroblast cells ( Fig 3A-B , S4B-D). Although many genes were regulated by REVERBα knockdown, only two were repressed at both timepoints (12&24 hours) and in both cell lines ( Fig. 3C , S4E,F).
One was PLOD2, a proline hydroxylase required for collagen processing. The second was TBPL1, a poorly characterized transcription factor. As the role of PLOD2 in collagen processing is already well characterized, we turned to TBPL1, and verified loss of protein expression with REVERBα knockdown (Fig. 3D ). Knockdown of TBPL1 caused a similar induction of αSMA expression to that seen with REVERBα knockdown (Fig. 3E) suggesting that REVERBα and TBPL1 contribute to the same pathway.
REVERBα and TBPL1 regulate Integrinβ1 expression
To decipher how REVERBα and/or TBPL1 suppress myofibroblast activation in fibrotic lungs and in the stiff cell culture environment, we focused on focal adhesions, crucial mechanotransducing elements that control myofibroblast activation (25) .
Knockdown of either REVERBα or TBPL1 resulted in increased sizes and numbers of vinculin/tensin1 positive focal adhesion complexes (Fig. 4A , S5A-C). This increase in size suggests progression to the super-mature focal adhesions involved in myofibroblast differentiation (25) . In contrast, overexpression of REVERBα or TBPL1 caused the opposite effect ( Fig. 4B, S5D,E) . Integrinβ1, the common subunit of all collagen1-binding integrins, has previously been linked to myofibroblast activation in the liver (26) , lung (27) and scleroderma (28) . Knockdown of either REVERBα or TBPL1 resulted in an increase in both size and number of integrinβ1-positive focal adhesion complexes (Fig. 4A, S5A ). Furthermore, knockdown of integrinβ1 prevented the induction of αSMA seen in fibroblasts cultures subjected to REVERBα knockdown ( Fig. 4C,D) , highlighting the requirement for integrinβ1 for REVERBαmediated myofibroblast activation (Fig. 4E ).
Circadian factors are associated with pulmonary fibrosis in humans
Several human factors have been associated with circadian, or sleep-deprivation strain, including evening chronotype, shift work and sleep duration. We therefore investigated whether these factors were associated with pulmonary fibrosis in the UK Biobank (29) (n=500,074). Following adjustment for known risk factors for pulmonary fibrosis (BMI, smoking, sex and age) short or long sleep duration (<7h or >7h) were associated with pulmonary fibrosis (Fig. 5A) , with the size of the odds ratio being greater than the established risk factors of age, sex or smoking in the multivariable model. Shift work (OR 1.353 95%CI 1.069-1.710) and evening chronotype (OR 1.040 95%CI 1.001-1.080) were also associated with pulmonary fibrosis (Tables S1-6) by a smaller degree, however this is comparable to other diseases were these variables are risk factors (30) (31) (32) .
Disordered clock gene expression occurs in idiopathic pulmonary fibrosis
To look for evidence of circadian clock disruption in idiopathic pulmonary fibrosis (IPF), we analysed lung gene expression in a previously published microarray from the lung research consortium (33) . Comparison with normal lung revealed significant differences in PER1/2, CRY 2 and REVERBα/β (Fig. 5B) , all encoding components of the negative feedback arm of the core circadian clock. In addition, TBPL1 was upregulated in pulmonary fibrosis, correlating with REVERBα expression (Fig. S4G) .
A REVERB ligand inhibits myofibroblast differentiation and represses collagen secretion in tissue from pulmonary fibrotic patients.
Finally, we tested whether a REVERBα ligand could repress pulmonary fibrosis. The well-characterized REVERBα agonist GSK4112 (34) repressed TGFβ-induced expression of αSMA (ACTA2) and collagen-1 (COL1A1) in primary human lung fibroblasts from patients with pulmonary fibrosis (Fig. 5C) . Similarly, TGFβ induction of αSMA and collagen 1 transcription was prevented by GSK4112 treatment in precision-cut human lung, organotypic slice cultures from healthy control subjects ( Fig. 5D ). Finally we studied the effects of this ligand in PCLS from IPF patients along with an Alk5 inhibitor; known to inhibit Col1a1 secretion (35) . GSK4112 repressed Col1a1 secretion (Fig. 5E ) in a similar manner to the Alk5 inhibitor.
Discussion:
Pulmonary fibrosis is an intractable and fatal disease. We have previously identified the lung as a highly circadian organ, and that responses to environmental insults are regulated and shaped by the circadian clock. Therefore we analysed mouse lung fibrosis, finding newly-emergent, and strong circadian oscillations driven by fibroblasts. The prevalent pro-fibrotic growth factor TGFβ was capable of transmitting timing information to recipient cells, and disruption to the core circadian clock in fibroblasts increased fibrotic response to bleomycin instillation. In vitro analysis identified a circuit linking the core clock through REVERBα, to TBPL1, and the focal adhesions important for myofibroblast activation. In human IPF lung tissue pharmacological targeting of the clock impacted a surrogate measure of fibrotic progression, and we found a new association between sleep duration, which is a product of the circadian clock, and risk of pulmonary fibrosis.
Several studies have found that circadian responses in the lung are gated through club cells (2) or macrophages (5) . A previous report suggested that the acute inflammatory phase (7 days) of the bleomycin response lay under circadian control (4), therefore, we investigated circadian function in developing fibrosis. Surprisingly, there were higher amplitude circadian oscillations in fibrotic tissue compared to normal lung tissue but these oscillations were desynchronous, suggesting a possible role for circadian mechanisms (36) . The process of fibrosis involves several different cell types including club cells, macrophages and fibroblasts (9) , but as genetic deletion of the only non-redundant circadian gene Bmal1 to the pericyte lineage stopped the emergent oscillations the importance of fibroblasts was established. The importance of the fibroblast was further confirmed by finding that REVERBα deletion in these cells impacted the fibrotic response, but disruption in other cell types was without effect. It is already known that circadian oscillations in fibroblasts are robust (37) , altering wound-healing (38, 39) .
Mechanistically, knockout or knockdown of REVERBα promoted myofibroblast activation in vitro, with the reverse effects seen with REVERBα overexpression.
Analysis of REVERBα gene targets revealed striking enrichment for a single
transcription factor, TBPL1, and the emergence of a coherent pathway converging on increased formation of integrinβ1 focal adhesion complexes. To the best of our knowledge TBPL1 has not been previously implicated in fibrotic disease, but we found its expression elevated in human IPF tissue. This and the elevated REVERBα expression is an apparent paradox, as both proteins inhibit myofibroblast activation.
Therefore, we hypothesize that the increase in both TBPL1 and REVERBα in fibrotic tissue results from tissue compensation in response to fibrosis, making it a promising therapeutic pathway. Integrinβ1, emerged as the final effector, and the focal adhesions associated with it have previously been established (26) to be important for myofibroblast activation.
We have successfully used large-scale human cohorts, such as the UK Biobank, to explore connections between measures of circadian strain (shiftwork, chronotype, and sleep) and prevalent disease (32, 40, 41) . Low prevalence diseases such as pulmonary fibrosis present unique challenges. To address this we identified people with pulmonary fibrosis participating in the UK Biobank (29) , and linked them with information from Hospital Episode Statistic data (42) . Importantly, patients were not screened for pulmonary fibrosis on enrolling in the Biobank therefore we cannot comment on causality, but it is clear that short sleep length is associated with pulmonary fibrosis and this is as least as strong as existing risk factors for this disease (43) indicating potential clinical relevance. An association with long sleep duration was also found which may be biological (44) or due to confounders (45) .
We, and others, have developed tool compounds capable of activating REVERBα (46, 47) . These permit extension of our studies to primary human tissue, which is hard to genetically manipulate. Here, we show a marked inhibition of the myofibroblast phenotype, blunted fibrotic response to TGFβ stimulation and reduced collagen-1 secretion in IPF precision cut lung slices. We, and others, have shown that these compounds have off target effects (46, 48) , therefore it is reassuring that knockdown and overexpression of REVERBα in human fibroblasts had similar effects to both our mice studies and also the ligand. The recent publication (48) that the only ligand with suitable PK for in vivo experiments has significant off target effects combined with the lack of translation from the mouse bleomycin model to the clinic (49) precludes an in vivo mouse experiment to confirm its therapeutic effectiveness. Furthermore tissue from IPF patients is emerging as a predictive model for human translation.
Taken together our results identify a surprising, and potent role for the core circadian clock factor REVERBα in the activation of myofibroblasts via a novel pathway incorporating a poorly characterised transcription factor TBPL1 which affects the development of pulmonary fibrosis.
Methods:
Mouse Lines: mPER2::luc transgenic mice were previously described (50) . The Reverbα fl/fl mouse (Rev-erbαDBD m ) and Cre drivers targeting club cells (CCSP icre ) and myeloid cells (Lysm cre ) are as previously described (1). The PDGFRβ cre mouse was a kind gift from Henderson and has been previously described (14) . The Bmal1 fl/fl mouse has been previously described (2) .
Cell Culture: MRC-5 cells or mLF-hT cells (16) were cultured in DMEM media.
In vivo Bleomycin:
Male mice were challenged intratracheally with Bleomycin (sigma) or Saline (vehicle).
Bioluminescence Microscopy: Precision-cut organotypic lung slices (PCLS) were prepared as described before (2) . Bioluminescence images were obtained using a 2.5x objective (Zeiss) and captured using a cooled Andor iXon Ultra camera over a 30 minute integration period.
Immunofluorescence: For αSMA staining, cells in 35mm dishes were fixed in 4% PFA/0.2% Triton X, followed by ice cold methanol fixation. For focal adhesions proteins cells were exposed to ice-cold cytoskeleton buffer (51) for 10 minutes followed by 4% PFA fixation for a further 10 minutes.
RNA-seq: siRNA transfected mLF-hT and Mrc5 cells were lysed and RNA was extracted using the ReliaPrep RNA miniprep system. RNA was sequenced on an Illumina HiSeq 4000. Analysis of these data was performed using the Ingenuity Pathway Analysis software (QIAGEN).
UK Biobank:
The UK biobank was accessed January 2019 and the data combined with the Hospital Episode data set (52) . Subjects were excluded a priori if they took sleep altering medication or had obstructive sleep apnoea.
Microarray Analysis: Geo2R (53) was used to analyse GSE47460 generated by the lung genome research consortium (54) .
Human PCLS: Precision cut lung slices were cut at 400µm on a vibrating microtome.
TGFβ, GSK4112 or Vehicle (DMSO) treatments were performed each day with the slices being lysed after 4 days for qPCR analysis or 7 days for supernatant analysis.
Additional methods can be found in the supplementary information
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